KMCRIC

Effects and safety of herbal medicines among community-dwelling residents during COVID-19 pandemic: A large prospective, randomized controlled trial (RCT).

Yan B, Jiang Z, Yuan J, Li M, Zeng J, Tang J, Lu ZK, Ding H, Xia J, Wang Q, Wang J, Xie H, Li W, Zhang N, Li H, Sang X, Wu L, Xiong X, Tang S, Li Y, Tao M, Xie C, Yu S.

Phytomedicine.

2021

85

153403.

10.1016/j.phymed.2020.153403.

33419674

http://www.ncbi.nlm.nih.gov/pubmed/33419674

Adolescent
Adult
COVID-19
China
Common Cold / prevention & control*
Drugs, Chinese Herbal / therapeutic use*
Female
Humans
Male
Middle Aged
Pandemics
Prospective Studies
Treatment Outcome
Young Adult

Common cold; Coronavirus disease 2019; Herbal medicine; Respiratory tract infection.

감기; 코로나2019; 한약; 호흡기 감염

KMCRIC 비평 보기 +

Background: Since the declaration of COVID-19 as a global pandemic by the World Health Organization, countries are struggling with a shortage of medical capacities. It would be essential if the risk for preventable comorbidities, such as the common cold, can be reduced or prevented, so that the scarce medical resources and facilities can be focused on COVID-19.

Purpose: To evaluate the effects of two herbal medicines (Jinhaoartemisia antipyretic granules and Huoxiangzhengqi oral liquids) in reducing the risk of the common cold in community-dwelling residents in China during the COVID-19 outbreak.

Study design: A prospective open-label, parallel-group, cluster-randomized controlled trial (RCT), was conducted in Chengdu, China.

Methods: A total of 22,065 participants from 11 communities were recruited during a period of one month. The trial started on 30 January and participants were followed up till 29 February 2020. Participants were randomly assigned to receive either a five-day herbal medicine therapy plus a reference manual or a reference manual only if they were allocated to the control group. The primary endpoint was the occurrence of patient-reported common cold symptoms. The secondary endpoint was the time in days from the receipt of herbal drugs/reference manual and the occurrence of the common cold symptoms.

Results: Use of herbal medicine reduced the risk of the common cold by 89.6% (95% CI, 52.9% to 97.7%) in all community-dwelling residents, and by 94.0% (95% CI, 52.1% to 99.2%) in residents aged between 16 and 59 years old. Sensitivity analyses showed similar results.

Conclusion: This community-based RCT found that the use of a herbal medicine therapy (Jinhaoartemisia antipyretic granules and Huoxiangzhengqi oral liquids) could significantly reduce the risks of the common cold among community-dwelling residents, suggesting that herbal medicine may be a useful approach for public health intervention to minimize preventable morbidity during COVID-19 outbreak.

영어